Doctors around the globe are becoming increasingly concerned as the mental health issues are exacerbating in the COVID-19 environment.
The Food and Drug Administration (FDA), USA has approved a nasal spray for people who are at high risk of suicide due to major depressive disorder.
Manufactured by the company Johnson & Johnson’s, the drug comes with a name Spravato. It contains esketamine, which is chemically related to ketamine, a potential anesthetic drug.
Reported by Dr. Gerard Sanacora, professor of psychiatry at Yale University :
"The drug's quick action is potentially important for suicidal patients because existing drugs typically can take weeks or longer before you really get noticeable clinical benefit"
The drug is strategically, a significant improvement in how people with intense suicidal thinking can be helped. So, a dose of esketamine could potentially lift up a person in the midst of an urgent depressive episode.
However, several side effects associated with esketamine are observed including dizziness, nausea, sedation vertigo, hypoesthesia, anxiety, lethargy, increased blood pressure and vomiting.